6-methoxy-2-[(4-phenylpiperidin-1-yl)methyl]-3,4-dihydro-2H-naphthalen-1-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 6-methoxy-2-[(4-phenylpiperidin-1-yl)methyl]-3,4-dihydro-2H-naphthalen-1-one
• 化学式: C₂₃H₂₇NO₂
• 分子量: 349.5
• InChiKey: QUZAAKMCCPRHKQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Novel compounds
  申请人：SmithKline Beecham SpA

  公开号：US20040024218A1

  公开（公告）日：2004-02-05

  Compounds of formula I, or a salt thereof or a hydrate thereof, as follows: 1 wherein X and Y are selected independently from hydrogen and aryl, which aryl is unsubstituted or substituted one or more times by hydroxy, hydroxyC 1-6 alkyl, C 1-6 alkoxyC 1-6 alkyl, aryl, heterocyclyl, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, arylC 1-6 alkoxy, C 1-6 alkyl, C 1-6 alkoxy or halo, which alkyl or alkoxy groups are unsubstituted or substituted one or more times by halo; m and n are independently 0 to 3, provided that m and n are not both 0; A represents a single bond or is —(CR pa R pb ) p — wherein p is 1-3 and R pa and R pb are selected independently from hydrogen, C 1-6 alkyl, C 1-6 alkoxy and halo, which alkyl or alkoxy groups are independently substituted one or more times by halo; B represents a C 4-8 saturated or unsaturated ring, which ring is unsubstituted or substituted one or more times by C 1-6 alkyl, C 1-6 alkoxy, aryl, aryloxy, hydroxy, oxo, halo, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, and C 1-6 alkylamido, which C 1-6 alkyl or C 1-6 alkoxy groups are unsubstituted or substituted one or more times by halo, which aryl group is unsubstituted or substituted one or more times by aryl, heterocyclyl, aryloxy, arylC 1-6 alkoxy, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, arylC 1-6 alkyl, hydroxy, C 1-6 alkenoxy, C 1-6 alkoxy, halo, or C 1-6 alkyl, which C 1-6 alkyl may be substituted one or more times by halo, and which aryl group is linked to said ring by a single bond or is benzo-condensed therewith are ligands of the ORL-1 receptor.

  式I的化合物，或其盐或水合物，如下所示：其中X和Y分别选择自氢和芳基，所述芳基未取代或被羟基、羟基C1-6烷基、C1-6烷氧基C1-6烷基、芳基、杂环烷基、氨基、C1-6烷基氨基、二(C1-6烷基)氨基、芳基C1-6烷氧基、C1-6烷基、C1-6烷氧基或卤素取代一次或多次，其中烷基或烷氧基基团未取代或被卤素取代一次或多次；m和n独立地为0到3，但要求m和n不能同时为0；A代表单键或为—(CRpaRpb)p—，其中p为1-3且Rpa和Rpb独立选择自氢、C1-6烷基、C1-6烷氧基和卤素，其中烷基或烷氧基基团独立地被卤素取代一次或多次；B代表C4-8饱和或不饱和环，所述环未取代或被C1-6烷基、C1-6烷氧基、芳基、芳氧基、羟基、氧代、卤素、氨基、C1-6烷基氨基、二(C1-6烷基)氨基和C1-6烷酰胺取代一次或多次，其中C1-6烷基或C1-6烷氧基基团未取代或被卤素取代一次或多次，所述芳基未取代或被芳基、杂环烷基、芳氧基、芳基C1-6烷氧基、氨基、C1-6烷基氨基、二(C1-6烷基)氨基、芳基C1-6烷基、羟基、C1-6烯氧基、C1-6烷氧基、卤素或C1-6烷基取代一次或多次，所述C1-6烷基可能被卤素取代一次或多次，所述芳基通过单键与所述环相连或与之苯并结合的化合物是ORL-1受体的配体。
• Lactam derivatives as antiarrhythmic agents
  申请人：——

  公开号：US20030114438A1

  公开（公告）日：2003-06-19

  Lactam derivatives of the formula 1 where X is -C(=O)NR 3′ -, -NR 3′ C(=O)-, -C(=NCN)NR 3′ -, -NR 3 ′C(=NCN)-, -CH 2 NR 3′ -, -CH(alkyl)NR 3′ -, -CH(COOalkyl)NR 3′ -, -CH(CH 2 OH)NR3 -,-C(CH 2 Oalkyl)-; R′ is halo, alkyl, cycloalkyl, alkyl(cycloalkyl), aryl, (aryl)alkyl, (aryl)alkenyl, (aryl)alkynyl, O-alkyl, O-alkenyl, O-aryl, O-alky(aryl), O-alkyl(heterocyclo), COO-alkyl, C)-alkyl, CO-amino, CO-substituted amino, alkyl-CO-amino, alkyl-CO-substituted amino, NHCO-alkyl, NHCO-aryl, NHCO-alkyl(aryl), NHCO-alkyl(heterocyclo), N(alkyl)CO-alkyl, N(alkyl)CO-aryl, N(alkyl)CO-heterocyclo, N(alkyl)CO-alkyl(aryl), N(alkyl)CO-alkyl(heterocyclo); R 2 is hydrogen, alkyl, halo, aryl, (aryl)alkyl, O-alkyl, amino, substituted amino; R 3 and R 3′ are the same or different and are independently selected from hydrogen, alkyl or alkyl(aryl); R 4 which can be bonded to a ring carbon or nitrogen, is selected from hydrogen, alkyl, alkenyl, alky(aryl), alkyl(heterocyclo), cycloalkyl, alkyl(cycloalkyl), alkyl-(amino), alkyl-(substituted amino), alkyl-NHCO(alkyl), alkyl-NHCO(aryl), alkyl-NHCO(heterocyclo), alkyl-NHCO(alkylaryl), alkyl-NHCO(alkylheterocyclo); and n is an integer of 0 to 2. These compounds have been found to be useful in the treatment of arrhythmia.

  这是一种公式为1的内酰胺衍生物，其中： X为-C(=O)NR3′-, -NR3′C(=O)-, -C(=NCN)NR3′-, -NR3′C(=NCN)-, -CH2NR3′-, -CH(烷基)NR3′-, -CH(COO烷基)NR3′-, -CH(CH2OH)NR3-, -C(CH2O烷基)-; R′为卤素，烷基，环烷基，烷基(环烷基)，芳基，(芳基)烷基，(芳基)烯基，(芳基)炔基，O-烷基，O-烯基，O-芳基，O-烷基(芳基)，O-烷基(杂环烷基)，COO-烷基，C)-烷基，CO-氨基，CO-取代氨基，烷基-CO-氨基，烷基-CO-取代氨基，NHCO-烷基，NHCO-芳基，NHCO-烷基(芳基)，NHCO-烷基(杂环烷基)，N(烷基)CO-烷基，N(烷基)CO-芳基，N(烷基)CO-杂环烷基，N(烷基)CO-烷基(芳基)，N(烷基)CO-烷基(杂环烷基)； R2为氢，烷基，卤素，芳基，(芳基)烷基，O-烷基，氨基，取代氨基； R3和R3′相同或不同，独立选择自氢，烷基或烷基(芳基)； R4可以与环上的碳或氮相结合，选择自氢，烷基，烯基，烷(芳基)，烷基(杂环烷基)，环烷基，烷基(环烷基)，烷基-(氨基)，烷基-(取代氨基)，烷基-NHCO(烷基)，烷基-NHCO(芳基)，烷基-NHCO(杂环烷基)，烷基-NHCO(烷基芳基)，烷基-NHCO(烷基杂环烷基)； n为0到2的整数。 这些化合物已被发现在心律失常的治疗中有用。
• N-SUBSTITUTED AZACYCLES, THEIR PREPARATION AND THEIR USE AS ORL-1 RECEPTOR LIGANDS
  申请人：Smithkline Beecham S.p.A.

  公开号：EP1129072A2

  公开（公告）日：2001-09-05
• US6048877A
  申请人：——

  公开号：US6048877A

  公开（公告）日：2000-04-11
• US6262068B1
  申请人：——

  公开号：US6262068B1

  公开（公告）日：2001-07-17